Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclopharm Limited (AU:CYC)
ASX:CYC
RESEARCH TOOLSreports
Cyclopharm Limited (CYC) Share Price & Analysis
4 Followers
CYC Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$1.72 - AU$3.15
Previous CloseAU$1.78
Volume1.98K
Average Volume (3M)23.93K
Market Cap
AU$167.66M
Enterprise ValueAU$151.69M
Total Cash (Recent Filing)AU$20.30M
Total Debt (Recent Filing)AU$4.33M
Price to Earnings (P/E)-35.1
Beta1.17
Next Earnings
Aug 21, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)-0.05
Shares OutstandingN/A
10 Day Avg. Volume3,158
30 Day Avg. Volume23,933
Standard Deviation0.16
R-Squared0.00204
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cyclopharm Limited News
PremiumCompany Announcements
Karst Peak Ends Major Stake in Cyclopharm
PremiumCompany Announcements
Cyclopharm Limited Plans New ASX QuotationsOptions Prices
Currently, No data available
---
Ownership Overview
28.80% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
71.20% Public Companies and
Individual Investors
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$1.72 and its highest was AU$3.15 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Currently, no data Available
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Aug 21, 2024 which is in 114 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 27, 2024. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.019.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Overvalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited does not currently pay dividends.
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 94,189,766 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
---
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYC Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.42%
12-Months-Change
Fundamentals
Return on Equity
-13.67%
Trailing 12-Months
Asset Growth
-7.32%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
---
CYC Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Holista Colltech Limited
―
Integral Diagnostics Ltd.
―
Genetic Signatures Ltd.
―
Best Analysts Covering CYC
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-29.38%
reiterated a buy rating 7 months ago
Copying John Hester's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.38% per trade.
---